Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityConvertible DebtCurrent AssetsCurrent LeasesCurrent TaxesFinished GoodsGoodwillGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term Deferred TaxNon-Current AssetsNon-Current Deferred Tax LiabilityOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Raw MaterialsReceivablesRetained EarningsShareholder's EquityShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury SharesWork In Process
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Lemaitre Vascular (LMAT) Cash & Equivalents (2016 - 2025)

Lemaitre Vascular (LMAT) has disclosed Cash & Equivalents for 16 consecutive years, with $28.2 million as the latest value for Q4 2025.

  • On a quarterly basis, Cash & Equivalents rose 10.29% to $28.2 million in Q4 2025 year-over-year; TTM through Dec 2025 was $28.2 million, a 10.29% increase, with the full-year FY2025 number at $28.2 million, up 10.29% from a year prior.
  • Cash & Equivalents was $28.2 million for Q4 2025 at Lemaitre Vascular, up from $25.5 million in the prior quarter.
  • In the past five years, Cash & Equivalents ranged from a high of $28.2 million in Q4 2025 to a low of $13.9 million in Q4 2021.
  • A 5-year average of $21.4 million and a median of $21.3 million in 2021 define the central range for Cash & Equivalents.
  • Biggest YoY gain for Cash & Equivalents was 114.96% in 2021; the steepest drop was 48.23% in 2021.
  • Lemaitre Vascular's Cash & Equivalents stood at $13.9 million in 2021, then surged by 38.1% to $19.1 million in 2022, then grew by 26.84% to $24.3 million in 2023, then increased by 5.53% to $25.6 million in 2024, then rose by 10.29% to $28.2 million in 2025.
  • Per Business Quant, the three most recent readings for LMAT's Cash & Equivalents are $28.2 million (Q4 2025), $25.5 million (Q3 2025), and $27.2 million (Q2 2025).